Integrated Molecular Risk Stratification and Measurable Residual Disease‐Guided Consolidation Improve Outcomes in Pediatric Non‐Down Syndrome Acute Megakaryoblastic Leukemia
Open Access
- 17 May 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71879
Abstract
Management of pediatric acute megakaryoblastic leukemia (AMKL) without Down syndrome (non‐DS‐AMKL) remains challenging due to suboptimal induction responses and poor survival. This study assessed the efficacy of fludarabine, cytarabine, granulocyte colony‐stimulating factor, and idarubicin (FLAG‐IDA) in non‐DS‐AMKL and evaluated the role of risk‐adapted consolidation strategies, including hematopoietic stem cell transplantation (HSCT) during first complete remission (CR1), guided by genetic profiles and measurable residual disease (MRD) dynamics. In this multicenter retrospective study from China, we analyzed 58 non‐DS‐AMKL patients treated with FLAG‐IDA ( n = 50) or daunorubicin, cytarabine, etoposide (DAE) ( n = 8) induction, followed by risk‐adapted consolidation. FLAG‐IDA demonstrated CR rates comparable to those with DAE (first‐course: 70.0% vs. 87.5%, p = 0.423; cumulative: 82.0% vs. 87.5%, p = 1.000). Compared with other AML subtypes, non‐DS‐AMKL showed inferior 5‐year overall survival (OS) (61.7% vs. 78.2%, p = 0.001) and event‐free survival (EFS) (58.5% vs. 68.8%, p = 0.045), attributable to a higher relapse rate (34.8% vs. 19.5%, p = 0.002). High‐risk genetics predicted worse outcomes. HSCT in CR1 significantly improved survival for high‐risk or poor responders. CR with MRD negativity after second induction predicted superior OS and EFS ( p < 0.001). Risk‐adapted HSCT and MRD‐guided stratification are critical for non‐DS‐AMKL management.Keywords
Funding Information
- National Key Clinical Specialty Discipline Construction Program of China (2021‐76)
This publication has 28 references indexed in Scilit:
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyBlood, 2015
- The biology of pediatric acute megakaryoblastic leukemiaBlood, 2015
- Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trialAnnals of Hematology, 2015
- Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 TrialJournal of Clinical Oncology, 2013
- Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children’s Oncology Group Study POG 9421Leukemia, 2012
- Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndromeBritish Journal of Haematology, 2008
- Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatmentLeukemia, 2005
- Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)Blood, 2005
- Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experienceBlood, 2001